Our purpose, strategy and culture

Our mission

2'48''

View video on YouTube

Our strategy

We are a focused biopharma company preventing and treating disease with specialty medicines, vaccines and general medicines. We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas to impact health at scale – respiratory, immunology & inflammation, oncology, HIV, and infectious diseases. Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems.

Our portfolio

Specialty medicines

Vaccines

General medicines

Specialty medicines are prescribed by specialist healthcare practitioners. Our portfolio of specialty medicines prevents and treats diseases, from HIV to respiratory diseases and cancer. In addition, we offer medicines for immune-mediated conditions, including the first new medicine in 50 years for lupus, a chronic autoimmune disease from which more than 4,000 Belgian patients suffer.

Our portfolio of more than 20 marketed vaccines, targeting infectious diseases from birth throughout adulthood, is one of the broadest in the industry. We deliver more than 1 million doses of our vaccines every day.

Belgium is home to the core of GSK's Vaccines division, with 3 major production sites in Wavre, Rixensart and Gembloux, as well as the international operations centre 'GSK Vaccines'. This represents the largest industrial network for vaccine manufacturing in the world.

General medicines are usually prescribed in primary care or community settings by general healthcare practitioners. They include inhalers for asthma and COPD to antibiotics. Every day, our general medicines make life better for millions of people all over the world. GSK in Belgium, with its portfolio of respiratory treatments, remains the industry leader.

More on our portfolio and how we treat disease

Our therapeutic areas

Respiratory, Immunology & Inflammation

We have a deep understanding of the underlying drivers of disease in different groups of patients with conditions like asthma and COPD. Our ambition is to redefine the future of respiratory medicine with a broad portfolio of next-generation treatments that work in distinct ways to help as many people as possible.

We’re building on our decades of knowledge in inflammatory mechanisms to target fibrotic lung, liver, and kidney disease.

Oncology

Our ambition is to help increase overall quality of life, maximise survival, and change the course of disease, expanding from our current focus on blood and gynaecologic cancers into lung and gastrointestinal cancers, as well as other solid tumours.

Our research uses precision medicine-based technology to match the right treatment to the right patient.

HIV

For nearly four decades, we’ve worked to improve the lives of people living with HIV or those who could benefit from prevention and protection from injection.

Our work in HIV is led by ViiV Healthcare, which we majority-own, with Pfizer and Shionogi as shareholders. ViiV Healthcare is the only company exclusively dedicated to treating and preventing HIV with an ambition to end the HIV epidemic.

Infectious diseases

We intend to have a positive impact on the lives of more than 2.5 billion people by the end of the decade, and a significant proportion of this will be through our work in infectious diseases. Our portfolio against infectious diseases is the broadest in the industry.

Our priorities include seasonal infections, chronic infections, common childhood diseases and rarer but critical conditions like meningitis. We also focus on bacterial infections where resistance is creating an urgent need for new treatments.

Our long-term priorities

By combining our understanding of the science of the immune system with cutting-edge technology, we can discover and develop new medicines and vaccines with the potential to transform people’s lives. Rapid advances in science and technology are unlocking new opportunities to prevent and treat disease. Our broad portfolio and pipeline continues to strengthen, with key milestones across our core therapeutic areas in 2024. To complement our in-house R&D, we partner with the world’s best minds to enable access to novel science and technology.

How we innovate

Facts and figures on R&D in Belgium

vaccine-candidates in the pipeline
17
euros investment in R&D in 2023
1.5 billion
scientific collaborations with Belgian universities and research centres
20

Facts and figures on R&D worldwide

fillings and approvals in 2024
23
vaccine-candidates in the pipeline
17
assets in our pipeline
71

With our strong momentum and improving outlook for sustained growth through the decade, we're confident in our ability to deliver human health impact at scale, worldwide.

Facts and figures on performance in Belgium

of exported vaccines to > 160 countries in 2023
99%
with more than 10% of all exports from Wallonia in 2023
1st exporter

Facts and figures on performance worldwide

vaccine doses delivered each day
>1 million
packs of medicines and doses of vaccines delivered in 2024
2.1 billion

Being a responsible business is an integral part of our strategy and culture. Our Trust priority supports our business performance and long-term growth. It helps us build trust, deliver returns to our shareholders, reduce risk, help people to thrive and to deliver sustainable health impact at scale. Six focus areas address what is most material to our business and most important to our stakeholders: access to healthcare, global health and health security, environment, inclusion, ethical standards, and product governance.

Our culture

Culture at GSK is something we all own. It powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. Our culture of being ambitious for patients, accountable for impact and doing the right thing are the foundations for how, together, we’ll deliver for our patients, shareholders and GSK people.

Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.

Two female employees walking in a building